NampEVA BioTherapeutics (NBT) LLC, is a biopharmaceutical company whose corporate mission is to deliver impactful and affordable medicines that transform health outcomes for patients in emerging countries and to concomitantly reinvest locally to promote medical, science and technology education.

NBT is in the process of raising funds to building and operate a 200,000 sq. ft. ultra-modern GMP pharmaceutical manufacturing facility with capacity for producing 150 Million tablets per month of high margin cancer specialty medicines, and a 500-bed specialist hospital equipped with state-of-the-art biomedical technologies to conduct WHO, EU and US FDA-approved clinical trials.

Prof. Dr. Alexzander A. A. Asea
President & CEO